06:19 EDT BeiGene (ONC) sees FY25 revenue $4.9B-$5.3B, consensus $5.09B
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene says USPTO invalidates Pharmacyclics’ ‘803 patent
- Reddit initiated, Roku upgraded: Wall Street’s top analyst calls
- BeiGene initiated with an Outperform at RBC Capital
- BeiGene’s Strategic Positioning and Growth Potential: A Buy Recommendation by Reni Benjamin
- BeiGene to discontinue development program for ociperlimab (BGB-A1217)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue